Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Abrams

Showing results (101-110 of 284) with videos related to

Pageof 29
Sort By:
Neurourology and Urodynamics|January 25, 2024
What is the best first choice oral drug therapy for OAB?Arun Sahai, Dudley Robinson, Paul Abrams, et al.
Neurourology and Urodynamics|November 13, 2024
Re: Khullar V, Lemmon B, Acar O, Abrams P, Vahabi B Does COVID-19 Cause or Worsen LUT Dysfunction, What Are the Mechanisms and Possible Treatments? ICI-RS 2023. Neurourol Urodyn 2024 Aug;43(6):1458-1463. doi: 101002/nau25441. Epub 2024 Mar 20. PMID: 38506116Vik Khullar, Bernadette Lemmon, Ömer Acar, et al.
Neurourology and Urodynamics|August 12, 2016
Psychometric equivalence of electronic and telephone completion of the ICIQ modulesAlan D Uren, Nikki Cotterill, Sophie E Parke, et al.
World Journal of Urology|August 20, 2011
Urinary urgency: a review of its assessment as the key symptom of the overactive bladder syndromePaul Abrams, Christopher R Chapple, Klaus-Peter Jünemann, et al.
Neurourology and Urodynamics|December 11, 2019
Can we improve our management of dysfunctional voiding in children and adults: International Consultation on Incontinence Research Society; ICI-RS2018?Tufan Tarcan, Alexander von Gontard, Apostolos Apostolidis, et al.
Neurourology and Urodynamics|February 14, 2016
Lower urinary tract symptoms and metabolic disorders: ICI-RS 2014Marie-Astrid Denys, Ralf Anding, Andrea Tubaro, et al.
Journal of Medical Economics|July 27, 2013
Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United KingdomWarren Mark Hart, Paul Abrams, Vicki Munro, et al.
BJU International|December 13, 2005
Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countriesDebra E Irwin, Ian Milsom, Zoe Kopp, et al.
The Journal of Urology|February 14, 2006
Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstructionPaul Abrams, Steven Kaplan, Hendrik J De Koning Gans, et al.
Neurourology and Urodynamics|May 2, 2015
A clinical perspective on the analysis and presentation of the number of incontinence episodes following treatment for OABReynaldo Martina, Richard Kay, Paul Abrams, et al.
Pageof 29

Showing results (101-110 of 284) with videos related to

Sort By:
Pageof 29
Neurourology and Urodynamics|January 25, 2024
What is the best first choice oral drug therapy for OAB?Arun Sahai, Dudley Robinson, Paul Abrams, et al.
Neurourology and Urodynamics|November 13, 2024
Re: Khullar V, Lemmon B, Acar O, Abrams P, Vahabi B Does COVID-19 Cause or Worsen LUT Dysfunction, What Are the Mechanisms and Possible Treatments? ICI-RS 2023. Neurourol Urodyn 2024 Aug;43(6):1458-1463. doi: 101002/nau25441. Epub 2024 Mar 20. PMID: 38506116Vik Khullar, Bernadette Lemmon, Ömer Acar, et al.
Neurourology and Urodynamics|August 12, 2016
Psychometric equivalence of electronic and telephone completion of the ICIQ modulesAlan D Uren, Nikki Cotterill, Sophie E Parke, et al.
World Journal of Urology|August 20, 2011
Urinary urgency: a review of its assessment as the key symptom of the overactive bladder syndromePaul Abrams, Christopher R Chapple, Klaus-Peter Jünemann, et al.
Neurourology and Urodynamics|December 11, 2019
Can we improve our management of dysfunctional voiding in children and adults: International Consultation on Incontinence Research Society; ICI-RS2018?Tufan Tarcan, Alexander von Gontard, Apostolos Apostolidis, et al.
Neurourology and Urodynamics|February 14, 2016
Lower urinary tract symptoms and metabolic disorders: ICI-RS 2014Marie-Astrid Denys, Ralf Anding, Andrea Tubaro, et al.
Journal of Medical Economics|July 27, 2013
Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United KingdomWarren Mark Hart, Paul Abrams, Vicki Munro, et al.
BJU International|December 13, 2005
Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countriesDebra E Irwin, Ian Milsom, Zoe Kopp, et al.
The Journal of Urology|February 14, 2006
Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstructionPaul Abrams, Steven Kaplan, Hendrik J De Koning Gans, et al.
Neurourology and Urodynamics|May 2, 2015
A clinical perspective on the analysis and presentation of the number of incontinence episodes following treatment for OABReynaldo Martina, Richard Kay, Paul Abrams, et al.
Pageof 29